Blocking Cxcr1/2 signaling with Cxcr1 antagonists, ELR+ chemokine analogues, or antibodies has been explored as a therapeutic approach in preclinical ALI models.[38, 39, 40] In humans, only a few studies have tested the effects of CXCR1 signaling inhibition on ARDS treatment.[43, 44] In a Phase 2 clinical trial including 56 patients with COVID‐19‐related ARDS, reparixin, a non‐competitive allosteric inhibitor of CXCR1 and CXCR2, was compared to standard care. The gene discussed is CXCR1; the disease is acute respiratory distress syndrome.